INT80018

Context Info Confidence 0.35 First Reported 1999 Last Reported 2011 Negated 1 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 2.84 Pain Relevance 0.09

nucleoplasm (ERBB4) mitochondrion (ERBB4) cytoplasm (ERBB4) cell proliferation (ERBB4) cytosol (ERBB4) signal transduction (ERBB4)

ERBB4 (Homo sapiens)

Pain Link Frequency Relevance Heat Chronic pancreatitis 1 94.88 Inflammation 37 50.00 Central nervous system 42 5.00 cva 6 5.00 Pain 5 5.00 cytokine 4 5.00 Bioavailability 4 5.00 addiction 4 5.00 tolerance 4 5.00 palliative 3 5.00

Disease Link Frequency Relevance Heat Cancer 160 99.68 Pancreatic Cancer 4 99.08 Pancreatitis 1 94.88 Inflammatory Breast Neoplasms 134 94.52 Metastasis 40 87.04 Shock 1 87.04 Apoptosis 7 68.92 Advanced Or Metastatic Breast Cancer 69 66.16 Breast Cancer 80 58.16 Stomach Cancer 47 56.80

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells.

erbB-4 Binding (immunoreactivity) of associated with cancer and pancreatic cancer

1) Confidence 0.35 Published 1999 Journal Int. J. Cancer Section Abstract Doc Link 9988227 Disease Relevance 0.83 Pain Relevance 0.09

Molecular interactions between HER2 and other members of its family (HER1 or EGFR, HER3 and HER4) have led to the development of new targeted therapies such as the anti-EGFR monoclonal antibody cetuximab, the anti-EGFR oral small molecule tyrosine kinase inhibitors erlotinib and gefitinib, and the dual EGFR-HER2 tyrosine kinase inhibitor lapatinib [96].

HER4 Binding (interactions) of

2) Confidence 0.17 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.57 Pain Relevance 0

No association was seen for ErbB4, PTEN or c-MYC.

ErbB4 Neg (No) Binding (association) of

3) Confidence 0.17 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0

EREG (epiregulin) belongs to the EGF growth factor family that binds both ERBB1 and ERBB4.

ERBB4 Binding (binds) of

4) Confidence 0.16 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 0.90 Pain Relevance 0

ErbB2, whilst having no exogenous ligand, is the preferred partner for heterodimerization with ErbB1, ErbB3 and ErbB4 as it amplifies the mitogenic signal with potent growth and survival effects.

ErbB4 Binding (heterodimerization) of

5) Confidence 0.13 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0

General Comments

This test has worked.